Karl Landsteiner University
Sankt Pölten, 3100, Austria
NCT Number: NCT06850519
Sneddon syndrome (SS) is a rare disorder with an incidence of about 4/million/year that affects mainly young and predominantly female adults. It is characterized by recurrent strokes and livedo reticularis, a purple reticular patterning of the skin. A genetic predisposition to this disease, for which there is still no single therapy, is being discussed. Our group recently identified a homozygous nonsense mutation within epidermal growth factor repeat (EGFr) 19 of NOTCH3 in two siblings of a consanguineous family with Sneddon syndrome and pediatric stroke. In an attempt to find other possible contributing genes in Sneddon syndrome patients with adult-onset stroke, we also searched for loss-of-function variants in genes downstream of NOTCH3. In doing so, we found 2 patients carrying heterozygous loss-of-function variants in the PALLD and ANGPTL4 genes. Our results suggest that a bi-allelic loss-of-function mutation in NOTCH3 is a cause of familial Sneddon syndrome with pediatric stroke and that impaired NOTCH3 signaling is an underlying disease mechanism in general. In addition, we have identified several other promising variants that are either located in genes associated with NOTCH3 signaling or play a role in vascular function and stroke.
Based on these results, we now want to investigate whether these aforementioned variants are detectable in a larger number of patients and additionally analyze whether other genetic variants also play a role in disease pathogenesis. The goal of our project is to identify risk variants for Sneddon syndrome by whole exome sequencing and subsequent conventional sequencing....
The detection of a risk gene would be a helpful tool for the diagnosis of Sneddon syndrome and a possible basis for new therapeutic approaches.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Sankt Pölten, 3100, Austria
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exome Sequencing and Sanger Sequencing
Time frame: 18 months
occurence of genetic variants in genes associated with Sneddon Syndrome
Karl Landsteiner University of Health Sciences
Other
A Study and Biobank to Identify Genetic Risk Factors in the Pathogenesis of the Sneddon Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06935578
Arterial Occlusive Diseases, Brain Diseases
Acquaviva delle Fonti, BA, Italy
View Trial DetailsNCT06092346
ADA2 protein, human, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS
Bethesda, Maryland, United States
View Trial DetailsNCT03841734
Arteritis, Arteritis, Giant Cell
Cannes, France
View Trial DetailsNCT03920722
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Diseases
Paris, France
View Trial Details